Hans Bentzen

1.2k total citations
21 papers, 337 citations indexed

About

Hans Bentzen is a scholar working on Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Hans Bentzen has authored 21 papers receiving a total of 337 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pathology and Forensic Medicine, 10 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Hans Bentzen's work include Lymphoma Diagnosis and Treatment (11 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Ion Transport and Channel Regulation (5 papers). Hans Bentzen is often cited by papers focused on Lymphoma Diagnosis and Treatment (11 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Ion Transport and Channel Regulation (5 papers). Hans Bentzen collaborates with scholars based in Denmark, Finland and Sweden. Hans Bentzen's co-authors include Robert S. Pedersen, E. B. Pedersen, Jesper Nørgaard Bech, Ole Nyvad, Erling Bjerregaard Pedersen, Michael Roost Clausen, Francesco d’Amore, Peter Kamper, Maja Dam Andersen and Martin Hutchings and has published in prestigious journals such as Blood, Kidney International and British Journal of Haematology.

In The Last Decade

Hans Bentzen

20 papers receiving 334 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hans Bentzen Denmark	11	131	122	105	78	74	21	337
Shunji Hashizume Japan	5	55 0.4×	170 1.4×	85 0.8×	26 0.3×	106 1.4×	9	461
C Augeri Italy	9	39 0.3×	44 0.4×	75 0.7×	72 0.9×	30 0.4×	14	365
Joe Matsuoka Japan	9	83 0.6×	65 0.5×	52 0.5×	39 0.5×	9 0.1×	17	306
Halil Gürhan Karabulut Türkiye	11	43 0.3×	29 0.2×	130 1.2×	28 0.4×	41 0.6×	42	369
Qiuju Wei China	12	76 0.6×	32 0.3×	130 1.2×	31 0.4×	45 0.6×	33	384
Hiroki Usuku Japan	13	77 0.6×	22 0.2×	200 1.9×	55 0.7×	228 3.1×	68	478
Amir H. Shemirani Hungary	13	124 0.9×	44 0.4×	53 0.5×	52 0.7×	44 0.6×	29	344
Shunya Matsumoto Japan	8	89 0.7×	59 0.5×	52 0.5×	62 0.8×	32 0.4×	47	282
Jonas Wiedemann United States	5	46 0.4×	17 0.1×	61 0.6×	90 1.2×	66 0.9×	8	309
Flora Cesario Italy	11	34 0.3×	109 0.9×	97 0.9×	87 1.1×	60 0.8×	19	504

Countries citing papers authored by Hans Bentzen

Since Specialization

Citations

This map shows the geographic impact of Hans Bentzen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans Bentzen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans Bentzen more than expected).

Fields of papers citing papers by Hans Bentzen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans Bentzen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans Bentzen. The network helps show where Hans Bentzen may publish in the future.

Co-authorship network of co-authors of Hans Bentzen

This figure shows the co-authorship network connecting the top 25 collaborators of Hans Bentzen. A scholar is included among the top collaborators of Hans Bentzen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans Bentzen. Hans Bentzen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Bentzen, Hans, Jon Riise, Jacob Haaber, et al.. (2025). Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long‐term follow‐up of the Nordic Lymphoma Group MCL6 Philemon trial. HemaSphere. 9(3). e70101–e70101.

2.

Kater, Arnon P., Jacob Haaber Christensen, Hans Bentzen, et al.. (2021). Subcutaneous Epcoritamab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Preliminary Results from the Epcore CLL-1 Trial. Blood. 138(Supplement 1). 2627–2627. 13 indexed citations

3.

Eskelund, Christian Winther, Konstantinos Dimopoulos, Arne Kolstad, et al.. (2020). Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3. HemaSphere. 5(1). e510–e510. 17 indexed citations

4.

Cunha‐Bang, Caspar da, Christian Brieghel, Christian Bjørn Poulsen, et al.. (2020). Richter’s transformation in patients with chronic lymphocytic leukaemia: a Nationwide Epidemiological Study. Leukemia & lymphoma. 61(6). 1435–1444. 13 indexed citations

5.

Madsen, Charlotte Bernhard, Trine Lindhardt Plesner, Hans Bentzen, et al.. (2020). Real world data on histological transformation in patients with follicular lymphoma: incidence, clinico-pathological risk factors and outcome in a nationwide Danish cohort. Leukemia & lymphoma. 61(11). 2584–2594. 11 indexed citations

6.

Andersen, Maja Dam, et al.. (2018). The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor. Leukemia & lymphoma. 60(4). 927–933. 22 indexed citations

7.

Madsen, Charlotte Bernhard, Michael Roost Clausen, Torben Plesner, et al.. (2018). Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study. Blood Advances. 2(13). 1562–1571. 9 indexed citations

8.

Clausen, Michael Roost, Sirpa Leppä, Peter de Nully Brown, et al.. (2016). The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- and T-Cell Phenotype - Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial). Blood. 128(22). 1782–1782. 9 indexed citations

9.

Ebbesen, Lene Hyldahl, et al.. (2014). SOX11 as a minimal residual disease marker for Mantle cell lymphoma. Leukemia Research. 38(8). 918–924. 7 indexed citations

10.

d’Amore, Francesco, Hans Bentzen, Elisa Jacobsen Pulczynski, et al.. (2014). Preliminary Clinical Experience on the Efficacy and Feasibility of a New Combination Regimen Consisting of Pixantrone, Etoposide, and Bendamustine with or without the Addition of Rituximab in Patients with Relapsed/Refractory Aggressive Non-Hodgkin Lymphomas. Blood. 124(21). 5435–5435. 5 indexed citations

11.

Bech, Jesper Nørgaard, et al.. (2013). Renal and Hormonal Effects of Systemic Nitric Oxide Inhibition in Patients With Congestive Heart Failure and in Healthy Control Subjects. Journal of Cardiac Failure. 19(11). 776–785. 2 indexed citations

12.

Bentzen, Hans, et al.. (2012). A highly sensitive and specific qPCR assay for quantification of the biomarker SOX11 in mantle cell lymphoma. European Journal Of Haematology. 89(5). 385–394. 15 indexed citations

13.

Bentzen, Hans, Robert S. Pedersen, Ole Nyvad, & E. B. Pedersen. (2004). Effect of exercise on natriuretic peptides in plasma and urine in chronic heart failure. International Journal of Cardiology. 93(2-3). 121–130. 29 indexed citations

14.

Bentzen, Hans, Robert S. Pedersen, H. B. Pedersen, Ole Nyvad, & E. B. Pedersen. (2003). Abnormal rhythmic oscillations of atrial natriuretic peptide and brain natriuretic peptide in heart failure. Clinical Science. 104(3). 303–303. 6 indexed citations

15.

Pedersen, Robert S., Hans Bentzen, Jesper Nørgaard Bech, Ole Nyvad, & Erling Bjerregaard Pedersen. (2003). Urinary aquaporin-2 in healthy humans and patients with liver cirrhosis and chronic heart failure during baseline conditions and after acute water load. Kidney International. 63(4). 1417–1425. 41 indexed citations

16.

Pedersen, Robert S., Hans Bentzen, Jesper Nørgaard Bech, & E. B. Pedersen. (2003). Effect of an acute oral lithium intake on urinary Aquaporin‐2 in healthy humans with and without simultaneous stimulation with hypertonic saline infusion. Scandinavian Journal of Clinical and Laboratory Investigation. 63(3). 181–194. 3 indexed citations

17.

Bentzen, Hans, Robert S. Pedersen, H. B. Pedersen, Ole Nyvad, & E. B. Pedersen. (2003). Abnormal rhythmic oscillations of atrial natriuretic peptide and brain natriuretic peptide in heart failure. Clinical Science. 104(3). 303–312. 7 indexed citations

18.

Bentzen, Hans, Robert S. Pedersen, Ole Nyvad, & E. B. Pedersen. (2002). Influence of training habits on exercise-induced changes in plasma atrial and brain natriuretic peptide and urinary excretion of aquaporin-2 in healthy man. Scandinavian Journal of Clinical and Laboratory Investigation. 62(7). 541–551. 9 indexed citations

19.

Pedersen, Robert S., Hans Bentzen, Jesper Nørgaard Bech, & E. B. Pedersen. (2001). Effect of an acute oral ibuprofen intake on urinary aquaporin-2 excretion in healthy humans. Scandinavian Journal of Clinical and Laboratory Investigation. 61(8). 631–640. 10 indexed citations

20.

Pedersen, Robert S., Hans Bentzen, Jesper Nørgaard Bech, & E. B. Pedersen. (2001). Effect of water deprivation and hypertonic saline infusion on urinary AQP2 excretion in healthy humans. American Journal of Physiology-Renal Physiology. 280(5). F860–F867. 84 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact